Parallel Fluidics Secures $7M Seed Round to Accelerate Microfluidic Development for the Next Generation of Life Science ToolsBOSTON, November 7, 2024-- Parallel Fluidics, the fastest microfluidic device manufacturer in the world, announced the close of its $7M seed round, led by J2 Ventures with participation from 8VC and Praxis.

Parallel Fluidics获得了700万美元的种子回合，以加速下一代生命科学工具的微流体开发。2024年11月7日，世界上速度最快的微流体设备制造商Parallel Fluidics宣布结束其700万美元的种子回合，由J2 Ventures牵头，8VC和Praxis参与。

The funding will help drive the growth of the company's on-demand design and manufacturing platform, expand its hardware and software solutions, and commercialize its new product, MV-2..

这笔资金将有助于推动公司按需设计和制造平台的发展，扩展其硬件和软件解决方案，并将其新产品MV-2商业化。

Parallel Fluidics accelerates the pace of discovery for scientific teams with the world's first on-demand microfluidic manufacturing service.

并行流体技术通过世界上第一个按需微流体制造服务加快了科学团队的发现步伐。

Parallel Fluidics accelerates the pace of discovery for scientific teams with the world's first on-demand microfluidic manufacturing service.

并行流体技术通过世界上第一个按需微流体制造服务加快了科学团队的发现步伐。

Diagnostics, drug discovery, precision medicine, sequencing, and cell therapy verticals are quickly shifting towards microfluidics, a technology where scientific tests can run at microscopic scales, allowing life science companies to achieve the next level of precision, speed, and throughput. Today, the global microfluidics market is a $32B industry currently and is expected to reach $117.13B by 2031 but is held back by design and supply chain challenges..

诊断学、药物发现、精准医学、测序和细胞治疗垂直领域正在迅速转向微流体技术，这是一种科学测试可以在微观尺度上运行的技术，使生命科学公司能够实现更高水平的精度、速度和吞吐量。今天，全球微流体市场目前是一个320亿美元的行业，预计到2031年将达到1171.3亿美元，但由于设计和供应链挑战而受到阻碍。

'Scientists and engineers developing the next breakthrough life science technology shouldn't be forced to reinvent the wheel when it comes to microfluidic systems, especially in applications like point-of-care diagnostics,' said Jon Bronson, PhD, Managing Partner and co-founder of J2 Ventures. 'With clients including academic labs, venture-backed startups and large biotech companies, Parallel Fluidics is making a huge impact with its on-demand microfluidic manufacturing services.

J2 Ventures管理合伙人兼联合创始人乔恩·布朗森（JonBronson）博士说，开发下一个突破性生命科学技术的科学家和工程师不应该被迫在微流体系统方面重新发明轮子，特别是在即时诊断等应用中平行流体公司的客户包括学术实验室、风险投资支持的初创公司和大型生物技术公司，它的按需微流体制造服务正在产生巨大影响。

Their products eliminate the common development risks, and accelerate the timeline from concept to launch by delivering production-ready devices in as little as three days – a true game changer for time-sensitive, cost-effective R&D.'.

他们的产品消除了常见的开发风险，并通过在短短三天内交付可生产的设备，加快了从概念到发布的时间表，这对于时间敏感、成本效益高的研发来说是一个真正的游戏规则改变者。”

'While more life science products are built with microfluidics, scientific teams have historically struggled with engineering and manufacturing challenges unrelated to their novel technology, such as flow control, automation, and the chip-to-world interface, said Josh Gomes, CEO and co-founder of Parallel Fluidics.

“虽然越来越多的生命科学产品是用微流体制造的，但科学团队一直在努力应对与他们的新技术无关的工程和制造挑战，如流量控制、自动化和芯片与世界的接口，并行流体公司（Parallel Fluidics）首席执行官兼联合创始人乔什·戈麦斯（JoshGomes）说。

'At Parallel Fluidics, we are on a mission to help scientific teams build scalable and reliable products to identify diseases faster and develop more effective medicines. With the new funding, we'll be able to scale up our on-demand manufacturing service, expand our hardware library, and develop new design and analytics software to power the next generation of life science tools.'.

“在并行流体公司，我们的使命是帮助科学团队构建可扩展且可靠的产品，以更快地识别疾病并开发更有效的药物。有了新的资金，我们将能够扩大按需制造服务，扩展硬件库，开发新的设计和分析软件，为下一代生命科学工具提供动力。”

Parallel Fluidics' hardware library offers an array of off-the-shelf hardware solutions to solve engineering challenges in microfluidics, reducing the cost and time for customers to develop new products. The MV-2 is Parallel's latest addition, an innovative microvalve that enables products to work at the point-of-care, like a doctor's office, clinic, or hospital, instead of only in laboratory environments.

Parallel Fluidics的硬件库提供了一系列现成的硬件解决方案，以解决微流体领域的工程挑战，减少客户开发新产品的成本和时间。MV-2是Parallel的最新产品，它是一种创新的微型阀，使产品能够在护理点工作，如医生的办公室、诊所或医院，而不仅仅是在实验室环境中。

Overture Life, an exciting life science startup simplifying in-vitro fertilization procedures, is using the MV-2 to control flow in their next-generation system..

Overture Life是一家简化体外受精程序的令人兴奋的生命科学初创公司，它正在使用MV-2控制其下一代系统中的流量。

'In order to provide advanced care in fertility treatments such as IVF, precise fluid control and the ability to manage sensitive biological samples without being wasteful are critical. Solutions like Parallel Fluidics' microfluidic systems are filling that gap with their microvalves and enabling faster, more reliable processes that can help us enhance patient outcomes and drive innovation in reproductive medicine,' said Lionel Matthys, Chief Product Officer, Overture Life..

“为了在IVF等生育治疗中提供先进的护理，精确的液体控制和管理敏感生物样本而不浪费的能力至关重要。Overture Life首席产品官莱昂内尔·马蒂斯（LionelMatthys）说，类似平行流体（Parallel Fluidics）微流体系统这样的解决方案正在用它们的微阀填补这一空白，并实现更快、更可靠的过程，帮助我们提高患者的治疗效果，推动生殖医学的创新。

About Parallel Fluidics

关于平行流体

Parallel Fluidics accelerates the pace of discovery for scientific teams with the world's first on-demand microfluidic manufacturing service. By offering production-grade devices from day one, Parallel eliminates the risks that slow down development and provides the shortest path from a concept to a successful microfluidic product.

并行流体技术通过世界上第一个按需微流体制造服务加快了科学团队的发现步伐。通过从第一天开始提供生产级设备，Parallel消除了阻碍开发的风险，并提供了从概念到成功微流体产品的最短路径。

Parallel Fluidics is already making a transformative impact across life sciences verticals such as diagnostics, drug discovery, precision medicine, sequencing, and cell therapy – empowering innovators to accelerate breakthroughs and improve patient outcomes. For more information about Parallel Fluidics, visit www.parallelfluidics.com..

平行流体技术已经在诊断学、药物发现、精准医学、测序和细胞治疗等生命科学垂直领域产生了变革性影响，使创新者能够加速突破并改善患者预后。有关并行流体的更多信息，请访问www.parallelfuidics.com。

About J2 Ventures

关于J2 Ventures

J2 Ventures is a $250M+ AUM deep-tech venture capital firm based in Boston, investing in sectors critical to national security and private sector advancements, including advanced computing, cybersecurity, telecom and infrastructure, and biomedical engineering. For more information about J2 Ventures and its initiatives, please visit https://www.j2vp.com/.Contact: .

J2 Ventures是一家规模超过2.5亿美元的高科技风险投资公司，总部位于波士顿，投资于对国家安全和私营部门进步至关重要的部门，包括先进计算、网络安全、电信和基础设施以及生物医学工程。有关J2 Ventures及其计划的更多信息，请访问https://www.j2vp.com/.Contact:。